Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 21, 2020

Study Completion Date

September 22, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib

DRUG

Dexamethasone

If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.

DRUG

Prednisone

f the patient was receiving prednisone, at the equivalent of \> 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.

DRUG

Methylprednisolone

If the patient was receiving methylprednisolone at the equivalent of \> 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.

DRUG

Lenalidomide

given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2

DRUG

Pomalidomide

administered PO at 4mg daily on days 1-21 of a 28 day cycle

Trial Locations (7)

12601

Hudson Valley Hem/Onc Associates, Poughkeepsie

32003

Cancer Specialists of North Florida, Fleming Island

44718

Gabrail Cancer Center, Canton

75701

Blood & Cancer Center of East Texas, Tyler

90069

James R Berenson, MD, Inc., West Hollywood

91307

Wellness Oncology and Hematology, West Hills

92024

California Cancer Associates for Research & Excellence (cCARE), Encinitas

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Oncotherapeutics

INDUSTRY

NCT02294357 - Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | Biotech Hunter | Biotech Hunter